| 1 |
MDR Tuberculosis Treatment |
|
| | Juan Espinosa-Pereiro, Adrian Sánchez-Montalvá, Maria Luisa Aznar, Maria Espiau | | | Medicina. 2022; 58(2): 188 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Ethionamide-induced gynecomastia: A rare case report |
|
| | Sourindra N. Banerjee, Rupam K. Ta, Md. Salim Mallick, Manish K. Munda | | | Egyptian Journal of Bronchology. 2017; 11(1): 70 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Cyclic di-GMP regulates Mycobacterium tuberculosis resistance to ethionamide |
|
| | Hai-Nan Zhang, Zhao-Wei Xu, He-Wei Jiang, Fan-Lin Wu, Xiang He, Yin Liu, Shu-Juan Guo, Yang Li, Li-Jun Bi, Jiao-Yu Deng, Xian-En Zhang, Sheng-Ce Tao | | | Scientific Reports. 2017; 7(1) | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications |
|
| | Geetha Ramachandran,Soumya Swaminathan | | | Drug Safety. 2015; | | | [Pubmed] [Google Scholar] [DOI] | |
|
